Company news
Aclaris Therapeutics, Inc. news in 2024
Aclaris Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 17, 2024
Aclaris Therapeutics Announces $80 Million Private Placement
November 17, 2024
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 5, 2024
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 16, 2024
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 9, 2024
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 6, 2024
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
July 15, 2024
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 5, 2024
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 6, 2024
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
April 29, 2024
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
April 22, 2024
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
February 26, 2024
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
January 15, 2024
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
January 9, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (November 2024)
Investor deck · 35 slides · Nov 18, 2024
- Q1 2024 Earnings Presentation
Earnings · 22 slides · May 7, 2024